[go: up one dir, main page]

WO2008120765A1 - 鎮痛用組成物 - Google Patents

鎮痛用組成物 Download PDF

Info

Publication number
WO2008120765A1
WO2008120765A1 PCT/JP2008/056239 JP2008056239W WO2008120765A1 WO 2008120765 A1 WO2008120765 A1 WO 2008120765A1 JP 2008056239 W JP2008056239 W JP 2008056239W WO 2008120765 A1 WO2008120765 A1 WO 2008120765A1
Authority
WO
WIPO (PCT)
Prior art keywords
acid
propionic
vitamin
analgesic
components
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/JP2008/056239
Other languages
English (en)
French (fr)
Inventor
Manabu Nozaki
Shigeki Sawamura
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kobayashi Pharmaceutical Co Ltd
Original Assignee
Kobayashi Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kobayashi Pharmaceutical Co Ltd filed Critical Kobayashi Pharmaceutical Co Ltd
Publication of WO2008120765A1 publication Critical patent/WO2008120765A1/ja
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4415—Pyridoxine, i.e. Vitamin B6
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A61K31/51—Thiamines, e.g. vitamin B1
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/525—Isoalloxazines, e.g. riboflavins, vitamin B2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7135—Compounds containing heavy metals
    • A61K31/714—Cobalamins, e.g. cyanocobalamin, i.e. vitamin B12
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nutrition Science (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Molecular Biology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

【課題】イブプロフェン等のプロピオン酸系鎮痛剤が示す鎮痛作用を増強し、かつ安全性に優れた鎮痛用組成物を提供すること。 【解決手段】プロピオン酸系鎮痛剤と２種以上のビタミンＢ類を含有する。前記ビタミンＢ類の配合量は前記プロピオン酸系鎮痛剤１重量部に対して総量で０．００１～１００重量部であることが好ましい。前記プロピオン酸系鎮痛剤がイブプロフェンであることが好ましく、前記ビタミンＢ類が、少なくともビタミンＢ１２又は葉酸を含有するものであることが好ましい。
PCT/JP2008/056239 2007-03-30 2008-03-28 鎮痛用組成物 Ceased WO2008120765A1 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2007-091793 2007-03-30
JP2007091793A JP5161472B2 (ja) 2007-03-30 2007-03-30 鎮痛用組成物

Publications (1)

Publication Number Publication Date
WO2008120765A1 true WO2008120765A1 (ja) 2008-10-09

Family

ID=39808345

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2008/056239 Ceased WO2008120765A1 (ja) 2007-03-30 2008-03-28 鎮痛用組成物

Country Status (2)

Country Link
JP (1) JP5161472B2 (ja)
WO (1) WO2008120765A1 (ja)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2018076305A (ja) * 2016-10-31 2018-05-17 エスエス製薬株式会社 医薬組成物
WO2021037871A1 (en) * 2019-08-26 2021-03-04 Dsm Ip Assets B.V. Solid oral dosage form comprising naproxen and vitamin b6
WO2021037874A1 (en) * 2019-08-26 2021-03-04 Dsm Ip Assets B.V. Solid oral dosage form comprising naproxen and vitamin b12

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011168580A (ja) * 2010-01-19 2011-09-01 Daiichi Sankyo Healthcare Co Ltd 医薬組成物
JP6106359B2 (ja) * 2010-12-13 2017-03-29 第一三共ヘルスケア株式会社 ロキソプロフェンナトリウムとビタミンｂ１を含有する固形製剤
JP7026457B2 (ja) * 2016-07-07 2022-02-28 第一三共ヘルスケア株式会社 ロキソプロフェン又はその塩及びビタミンｂ１２類を含有する経口用医薬組成物

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000050028A1 (en) * 1999-02-24 2000-08-31 Andrew Peter Worsley Compositions for the treatment of pain
WO2000056404A1 (en) * 1999-03-24 2000-09-28 Kilgowan Limited Formulations for treatment of pain comprising vitamin b12 and phenylanine

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000050028A1 (en) * 1999-02-24 2000-08-31 Andrew Peter Worsley Compositions for the treatment of pain
WO2000056404A1 (en) * 1999-03-24 2000-09-28 Kilgowan Limited Formulations for treatment of pain comprising vitamin b12 and phenylanine

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
BRUGGEMAN G. ET AL.: "Results of a double-blind study of diclofenac + vitamin B1, B6, B12 versus diclofenac in patients with acute pain of the lumbar vertebrae", KLIN. WOCHENSCHR., vol. 68, no. 2, 1990, pages 116 - 120 *
GLUECK C.J. ET AL.: "Stromelysin-1 5A/6A and eNOS T-786C polymorphisms, MTHFR C677T and A1298C mutations, and cigarette-cannabis smoking: a pilot, hypothesis-generating study of gene-environment pathophysiological associations with Buerger's disease", CLIN. APPL. THROMB. HEMOST., vol. 12, no. 4, 2006, pages 427 - 439 *
O'SHAUGHNESSY J.A. ET AL.: "Phase II study of pemetrexed in patients pretreated with an anthracycline, a taxane, and capecitabine for advanced breast cancer", CLIN. BREAST CANCER, vol. 6, no. 2, 2005, pages 143 - 149 *
TANAKA C.: "New Pharmacology, (4th revised edition)", 2002, NANKODO CO., LTD., pages: 484 - 485 *

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2018076305A (ja) * 2016-10-31 2018-05-17 エスエス製薬株式会社 医薬組成物
JP7523879B2 (ja) 2016-10-31 2024-07-29 エスエス製薬株式会社 医薬組成物
WO2021037871A1 (en) * 2019-08-26 2021-03-04 Dsm Ip Assets B.V. Solid oral dosage form comprising naproxen and vitamin b6
WO2021037874A1 (en) * 2019-08-26 2021-03-04 Dsm Ip Assets B.V. Solid oral dosage form comprising naproxen and vitamin b12
CN114302713A (zh) * 2019-08-26 2022-04-08 帝斯曼知识产权资产管理有限公司 包含萘普生和维生素b6的固体口服剂型

Also Published As

Publication number Publication date
JP2008247822A (ja) 2008-10-16
JP5161472B2 (ja) 2013-03-13

Similar Documents

Publication Publication Date Title
WO2009108720A3 (en) Antagonists of prostaglandin d2 receptors
WO2008013840A3 (en) Erastin analogs and uses thereof
WO2008120765A1 (ja) 鎮痛用組成物
WO2010054113A3 (en) Cycloalkane[b]azaindole antagonists of prostaglandin d2 receptors
WO2008116135A3 (en) Topical formulations having enhanced bioavailability
WO2010037059A3 (en) Heteroaryl antagonists of prostaglandin d2 receptors
WO2010003127A3 (en) Antagonists of prostaglandin d2 receptors
WO2010042652A3 (en) Heteroalkyl biphenyl antagonists of prostaglandin d2 receptors
WO2010111406A3 (en) Purine derivatives useful as anti - cancer agents
EP2123257A3 (en) Stable high Vitamin C content polyol-in-oil emulsified system and its preparation
WO2009140642A3 (en) Tricyclic antagonists of prostaglandin d2 receptors
EA201001285A1 (ru) Применение 25-oh d3 для воздействия на физиологию мышц человека
WO2008070268A3 (en) Pharmaceutical compositions
WO2010085820A3 (en) Tricyclic compounds as antagonists of prostaglandin d2 receptors
WO2009044648A1 (ja) 抗アレルゲン剤
CR10305A (es) "derivados sustituidos de cromanol y su uso.
WO2009102707A3 (en) Substituted oxazaphosphorines
WO2010116382A3 (en) Stable pharmaceutical compositions of diclofenac
ZA201000126B (en) Antimicrobial composition
MX2010001243A (es) Composicion anti-inflamatoria.
WO2008155651A3 (en) Inositol for induction of ovulation
WO2007044611A3 (en) Methods for weight management
WO2011027344A3 (en) Combination of vitamin e and beta-glycosphingolipids in compositions and methods for preventing and treating hepatic disorders
NZ596168A (en) Use of delta-tocopheryl-carbohydrate as a depigmenting agent
NZ600960A (en) Liquid compositions comprising vitamin d and uses thereof

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08739357

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 08739357

Country of ref document: EP

Kind code of ref document: A1